Oraya TherapyTM Stereotactic Radiotherapy for Wet AMD

UPCOMING EVENTS

EURETINA_2015

15th EURETINA Congress

Join Oraya Therapeutics at EURETINA 2015
September 17-20, 2015 | Nice, France

Visit Oraya Therapeutics Stand #M 100

ORAYA SATELLITE SEMINAR
Saturday, September 19, 2015
10:00am – 11:00am | Room: Clio

Oraya Therapy for Wet AMD: Real World Clinical Outcomes

Moderator
Mr. Timothy Jackson, PhD, FRCOphth

Featured Speakers
Professor Dr. Frank Zimmermann
Dr. Mahdy Ranjbar
Dr. Katja Hatz
Mr. Christopher Brand
Read More >

2015 Annual Meeting of the German Ophthalmological Society (DOG)

Visit Oraya Therapeutics Stand F3.03
October 1-4, 2015 | Berlin, Germany

NEWS AND ANNOUNCEMENTS

The Ophthalmology team at Heart of England NHS Foundation Trust is celebrating after it was shortlisted for a prestigious award for its work with an innovative treatment which has proved life-changing for sufferers of a chronic eye disease… Read Press Release >

Treatment Locations
home_map

The Oraya Therapy is available in Germany, Switzerland and the United Kingdom. For more information, call 0800-283-2243 in Germany, 41-61-4266000 in Switzerland, and 0800-690-6495 in the United Kingdom.

TreatmentCenters_sm

WHAT IS AMD?

Age-Related Macular Degeneration (AMD) is a progressive disease that causes loss of central vision leading to blindness. It is the primary cause of vision loss for seniors in the industrialized world. While there is no cure for AMD, the Oraya Therapy™ for Wet AMD is an exciting new treatment.   More >

WHO IS ORAYA?

Founded in 2007, Oraya® Therapeutics, Inc. is a privately held company developing an innovative and non-invasive therapy designed to advance the treatment options for wet AMD.  More >

WHY ORAYA THERAPY?

Physicians and patients require a new option and a new vision for the treatment of wet AMD. Oraya Therapy— intended as a one-time, non-invasive procedure—uses a low-voltage, stereotactic approach. It delivers precisely controlled X-rays confined to the diseased area of interest, sparing the surrounding structures of the eye.  More >

————————————————

Published Articles
Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration: Year 2 Results of the INTREPID Study

Published in Ophthalmology, January 2015.
Free Download >

© 2015 All rights reserved. Oraya Therapeutics, Inc. The IRay® is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the ORAYA THERAPY section of this website. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.